In Silico Trials

Reduce, Refine, and partially Replace Human and Animal Trials

Computational modelling & simulations

carefully engineer medical product innovations,
explicitly optimise clinical outcomes, and
thoroughly assess side effects before being marketed

Benefits

Better Patient Outcomes
Less Risk to Patients
Better Device Designs
Fail Faster and Earlier
Reduce R&D Costs
Reduced Animal Harm

Trials on Real vs In Silico Patients - an exemplar

A typical Randomised Controlled Trial (RCT) of a cardiovascular device can take 6 to 8 years from design to publication, and cost £40-80m. Such a device can go to market with testing on less than 500 patients

We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy statement for more information regarding cookies and other third-party tracking that may be enabled.